How common is "Nausea" with PT-141?

common, moderate - Vyleesi label.

Side effects

PT-141 (Bremelanotide / Vyleesi) - side effects

Nausea is the most common effect (40% in clinical trials) — especially the first 1-2 doses, with tolerance building afterward. Transient blood pressure elevation is documented in the Vyleesi approval.

Documented effects

Sorted by severity. Source cited when published.

Nausea

moderate·common·Vyleesi label

Focal hyperpigmentation (rare, >8/month)

moderate·rare

Transient BP rise (5-10 mmHg)

mild·common

Flushing

mild·common

Headache

mild·common

Injection-site reaction

mild·common

Contraindications

Uncontrolled hypertension; known cardiovascular disease.

Dosing

PT-141 dosing protocol

Encyclopedia

Full scientific profile for PT-141

Disclaimer: data is curated from research literature for in-vitro experiments. This is not medical advice.

Last reviewed: 6 May 2026by PeptidLabs Editorial

Side effects

PT-141 (Bremelanotide / Vyleesi) - side effects

Documented effects

Sorted by severity. Source cited when published.

Nausea

moderate·common·Vyleesi label

Focal hyperpigmentation (rare, >8/month)

moderate·rare

Transient BP rise (5-10 mmHg)

mild·common

Flushing

mild·common

Headache

mild·common

Injection-site reaction

mild·common

Contraindications

Uncontrolled hypertension; known cardiovascular disease.

Dosing

PT-141 dosing protocol

Encyclopedia

Full scientific profile for PT-141

Disclaimer: data is curated from research literature for in-vitro experiments. This is not medical advice.

Last reviewed: 6 May 2026by PeptidLabs Editorial